Biobucks: why reversion rights beat headline deal value

September 27, 2026 · 5 min · Free, with full transcript

What should a biotech CFO actually negotiate in a milestone-based pharma partnership, when the headline number is mostly contingent? The position here is blunt: a 900 million dollar deal with 40 million upfront is aspiration, and with only 5 to 7 percent of oncology drugs entering Phase 1 reaching approval, most of that value should be priced at pennies on the dollar. You walk away able to rebuild deal value using stage by stage transition probabilities, write reversion rights that return the compound and the safety file together, set diligence obligations with minimum annual spend and fixed development dates, and judge an 8 to 15 percent royalty range against a thin upfront. Vertex style clean reversion is the benchmark.

Listen to the podcast

4 min

Chapters

Key takeaways

  • Risk-adjust every milestone using real stage by stage transition probabilities, starting from the 5 to 7 percent Phase 1 to approval rate in oncology.
  • Insist that reversion rights return the clinical data and safety file, not only the compound and patent.
  • Write diligence obligations with minimum annual spend and fixed development dates, with the licence reverting if the partner misses them.
  • Spend your leverage at signing, before the ink dries, since that is the only moment you hold the asset outright.
  • Trade away upfront cash if you must, but never trade reversion, data return or diligence obligations.
Read the full transcript

Host:Leaders Insights. Today: Pharma partnership terms that protect your pipeline when the science goes sideways. Three weeks ago a mid-cap biotech watched a partner walk away from a Phase 2 program and kept exactly nothing — no data rights, no reversion, no cash. That's the nightmare, right?

Expert:It's the nightmare, and it's avoidable. The deal was signed in 2021 with a clause that let the partner terminate "for convenience" with ninety days' notice and no obligation to hand back the clinical data. So the biotech funded four years of development and ended up with a hole where their lead asset used to be.

Host:But every founder tells me milestone deals are how they survive. Cash upfront, cash at each stage. What's wrong with that?

Expert:Nothing's wrong with the structure. The problem is the biotech reads the headline number and ignores the shape of the payments. Someone signs a deal worth, say, 900 million dollars in "biobucks" — total potential value across every milestone — and 40 million of that is actually upfront. The other 860 is contingent on approvals that hit maybe one time in ten.

Host:So the nine-figure press release is mostly fiction.

Expert:Mostly aspiration. And here's the number that matters: in oncology, roughly 5 to 7 percent of drugs entering Phase 1 — the first human safety trials — ever reach approval. So if 90 percent of your deal value sits behind a Phase 3 readout, you should price it at pennies on the dollar in your own model, not at face value.

Host:Give me the term that actually protects the downside, then. Not theory — a clause.

Expert:Reversion rights. If the partner shelves or terminates the program, the asset and all the data come back to you cleanly, with a defined licence to anything they generated. Vertex structured deals like this years ago — walk away, and the science reverts, no ransom. That single clause is the difference between a setback and a company-ending event.

Host:You keep saying "data." Why is the data the thing people forget to fight for?

Expert:Because in a decade-long program the data is the asset. The molecule without the trial results is a chemistry lesson. If your partner runs the study, controls the database, and terminates, you can own the patent and still be unable to talk to another buyer — you've got nothing to show them. I've seen a reversion clause that returned the compound but not the safety file. Useless.

Host:Let's talk incentive alignment, because that's the phrase everyone uses and nobody defines.

Expert:Alignment means the partner loses money when they slow-walk your drug. Concretely: diligence obligations with teeth. A clause that says the partner must spend a minimum amount per year and hit development steps by fixed dates, or the licence reverts. Without it, a big pharma can park your asset for three years while they prioritise their internal pipeline, and you can't do a thing.

Host:Doesn't a small biotech have zero leverage to demand that from a partner ten times its size?

Expert:Less than they think, more than they act on. The leverage is at signing, before the ink dries — that's the only moment you hold the asset outright. One number to anchor on: the royalty. A typical range is 8 to 15 percent of net sales. If you give away the high end and take a thin upfront, you've mortgaged the one revenue stream that pays out if the drug actually works.

Host:So what should a CFO trade away and what should they never trade?

Expert:Trade the upfront. Take less cash today if you must — that's recoverable. Never trade reversion, never trade the data return, never trade the diligence obligation. Those three are what keep you alive when the science goes sideways, which statistically it will more often than not.

Host:One concrete move for the CFO listening who's negotiating a term sheet this quarter.

Expert:Open your model and rebuild the deal value using real transition probabilities — that 5 to 7 percent survival rate, stage by stage. If the risk-adjusted number is a fraction of the headline, and it will be, walk back into the room and spend your remaining leverage on reversion and diligence, not on a bigger biobucks number nobody will ever pay.

Host:The press release is vanity. The reversion clause is survival.

Expert:Put that on the wall.

Host:Sources for today's episode: Accounting Today, Financial Times, CNBC Finance, CFO Dive. That's it. The CFO decision tools are live at mba-training.com.

Read and go deeper